{"slug":"mds","tag":"mds","variants":["mds","MDS"],"description":"No description yet","count":4,"kinds":{"person":4},"related":[{"slug":"trialist","tag":"trialist","shared":2},{"slug":"anaemia","tag":"anaemia","shared":1},{"slug":"clinician-scientist","tag":"clinician-scientist","shared":1},{"slug":"epigenetics","tag":"epigenetics","shared":1},{"slug":"france","tag":"france","shared":1},{"slug":"haematology","tag":"haematology","shared":1},{"slug":"leadership","tag":"leadership","shared":1}],"records":[{"id":"marc-raaijmakers","kind":"person","name":"Marc H.G.P. Raaijmakers","route":"/people/marc-raaijmakers/","tldr":"Erasmus MC haematologist and HOVON Vice Chair known for research on the bone marrow microenvironment in MDS."},{"id":"uwe-platzbecker","kind":"person","name":"Uwe Platzbecker","route":"/people/uwe-platzbecker/","tldr":"Led MEDALIST and COMMANDS, which made luspatercept a first-line treatment for anaemia in lower-risk MDS."},{"id":"pierre-fenaux","kind":"person","name":"Pierre Fenaux","route":"/people/pierre-fenaux/","tldr":"Led AZA-001, which showed azacitidine extends survival in high-risk MDS and made hypomethylating agents standard."},{"id":"amer-zeidan","kind":"person","name":"Amer M. Zeidan","route":"/people/amer-zeidan/","tldr":"Yale haematologist who led VERONA, the trial that asked whether adding venetoclax to azacitidine helps people with higher-risk myelodysplastic syndromes, and found it did not lengthen survival."}]}